Remove clinical CBD
article thumbnail

PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex

Fierce Pharma

PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex. Thu, 12/01/2022 - 11:05.

109
109
article thumbnail

Research Indicates Clinical Trials Are Needed to Determine CBD Benefits for Heart Disease

Pharmacy Times

Patients should discuss efficacy and potential drug interactions with clinicians before use, study authors indicate.

132
132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves IND for clinical trial evaluating CBD-based drug

Outsourcing Pharma

The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientificâs Nantheia ATL5, a candidate for treating opioid use disorder.

FDA 97
article thumbnail

Benefits of Medical Marijuana for Epilepsy

BuzzRx

Food and Drug Administration approved Epidiolex , the first plant-based CBD (cannabidiol) formulation for the treatment of two rare forms of childhood-onset epilepsy: Lennox-Gastaut syndrome (LGS) and Dravet syndrome. This CBD oral solution can be used in adults and children as young as 1 year old. This has led the U.S.

FDA 64
article thumbnail

What to tell patients about CBD and blood thinners

The Checkup by Singlecare

The use of cannabidiol (CBD), whether in oils, gummies, or creams, is rapidly growing in the United States. In 2022 alone, the consumer market size for CBD reached around $16 billion and is expected to nearly quadruple by 2032. Taking CBD and blood thinners, in particular, could lead to serious drug interactions and adverse effects.

Dosage 52
article thumbnail

Full spectrum cannabidiol reduces anxiety and improves cognition

Hospital Pharmacy Europe

Cannabidiol (CBD) given as a full-spectrum (i.e., For example, CBD has been found to be effective in patients with generalised social anxiety disorder although to date, only one randomised trial has been undertaken. While previous research has examined the anxiolytic action of CBD, this is usually with a highly purified version.

article thumbnail

Incannex engages QPS for CannQuit and ReneCann

Pharmaceutical Technology

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. The company will help in managing the clinical trials of the products once the regulators provide approvals for the proposed research and development programmes.